Niagen Bioscience, Inc.
Niagen Bioscience is a global bioscience company focused on healthy aging and research into NAD+, a coenzyme involved in cellular metabolism. It develops and commercializes Niagen®, a form of nicotinamide riboside, as a food-grade ingredient and pharmaceutical-grade ingredient. Its Tru Niagen® brand offers finished dietary supplements sold directly to consumers and through distributors, online marketplaces and retail partners. Niagen Bioscience supplies food-grade Niagen® to consumer-product manufacturers and pharmaceutical-grade Niagen® to 503B outsourcing facilities and compounding pharmacies for prescription formulations. It also conducts research and development into potential pharmaceutical applications for NAD+ precursors. The company earns money from sales of consumer supplements and ingredient products. It also historically provided analytical reference standards and research services to customers in food, dietary supplement, cosmetic, pharmaceutical and life sciences industries, but sold that segment in 2026. Niagen Bioscience is headquartered in Los Angeles, California.
No enriched coverage for $NAGE in the last 7 days.
No SEC Form 4 filings for $NAGE in the last 30 days.
See all $NAGE insider activity →Canaccord Genuity kept its Buy rating on Niagen Bioscience but reduced its price target from $10 to $9, a 10% cut. The new target suggests a 286.3% upside from the Oct 30 closing price of $2.33.
Niagen Bioscience (NASDAQ: NAGE) published two pilot studies showing injectable Niagen was well-tolerated and associated with reduced fatigue, improved sleep, and skin health. The studies involved 39 adults with elevated fatigue. The company launched a liquid Niagen At-Home Injection Kit, aiming to scale its telehealth platform. Results are exploratory and require larger, placebo-controlled studies.
Canaccord Genuity reiterated a Buy rating and $10.00 price target on Niagen Bioscience (NAGE) after meeting with management. The company aims to expand beyond supplements into healthy aging, therapeutics, and skincare. Despite slower growth in 2026, Canaccord expects a return to double-digit growth in late 2026 and 2027. NAGE trades at 1.2x EV/Sales and 11.7x EV/EBITDA, below peer M&A averages.
Recent NAGE coverage spans financial news, technology and regulation.
Canaccord Genuity kept its Buy rating on Niagen Bioscience but reduced its price target from $10 to $9, a 10% cut. The new target suggests a 286.3% upside from the Oct 30 closing price of $2.33.
Positive early‑stage clinical data may boost investor sentiment for NAGE.
Positive catalyst from regulatory designations and analyst upgrade may lift the stock.
The 8-K combines quarterly financial results with new commercialization (telehealth) and new pharma pipeline progress (FDA RPD and EMA OMPD for NB4168).
This is a new disclosed 5.2% beneficial stake by BlackRock, which can shift ownership perception and liquidity/positioning expectations.
AlphAI scores every news story that mentions NAGE with an AI model for sentiment and relevance, and aggregates insider trades from Niagen Bioscience, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Canaccord Genuity kept its Buy rating on Niagen Bioscience but reduced its price target from $10 to $9, a 10% cut. The new target suggests a 286.3% upside from the Oct 30 closing price of $2.33.
1 min readNiagen Bioscience (NASDAQ: NAGE) published two pilot studies showing injectable Niagen was well-tolerated and associated with reduced fatigue, improved sleep, and skin health. The studies involved 39 adults with elevated fatigue. The company launched a liquid Niagen At-Home Injection Kit, aiming to scale its telehealth platform. Results are exploratory and require larger, placebo-controlled studies.
2 min readCanaccord Genuity reiterated a Buy rating and $10.00 price target on Niagen Bioscience (NAGE) after meeting with management. The company aims to expand beyond supplements into healthy aging, therapeutics, and skincare. Despite slower growth in 2026, Canaccord expects a return to double-digit growth in late 2026 and 2027. NAGE trades at 1.2x EV/Sales and 11.7x EV/EBITDA, below peer M&A averages.
2 min readNiagen Bioscience, Inc. (NAGE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results Launched pharmaceutical program targeting rare genetic diseases and aging related disorders in July Launched Niagen Plus telehealth platform Net sales of $29.8 million, including $24.2 million from Tru Niagen G
6 min readBlackRock, Inc. filed a Schedule 13G reporting beneficial ownership of 4,161,626 shares of Niagen Bioscience, Inc. common stock, or 5.2% of the class, as of a signature date of July 29, 2026. The filing shows sole voting power of 4,097,677 shares and sole dispositive power of 4,161,626 shares.
4 min readNiagen Bioscience (NASDAQ: NAGE) said the FDA granted Rare Pediatric Disease designation to its lead small-molecule candidate NB4168 for Ataxia Telangiectasia (A-T). The company also reported the EMA granted Orphan Medicinal Product designation for NB4168 in the EU. The designations recognize A-T as serious and life-threatening and provide development incentives.
2 min readNiagen Bioscience shares fell 0.3% pre-open to $3.38. The company said the U.S. FDA granted Rare Pediatric Disease Designation and the European Medicines Agency granted Orphan Medicinal Product Designation for NB4168, its drug candidate for Ataxia Telangiectasia. The article cites prior July disclosures and a Freedom Capital upgrade, noting the move as “sell the news.”
3 min readNiagen Bioscience (NASDAQ: NAGE) said it launched a regulated drug development program via its wholly owned subsidiary NAD Pharmaceuticals. The first candidate, NB4168, is a proprietary oral derivative of NR aimed at higher bioavailability. Initial indication is Ataxia Telangiectasia, a rare ATM-gene disease with no FDA-approved therapies, and nonclinical PK data show higher blood exposure than NR chloride.
4 min readNiagen Bioscience, Inc. (NAGE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. cdxc-20260624 0001386570 FALSE 0001386570 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
3 min readNiagen Bioscience (NAGE) delivered earnings and revenue surprises of +150.00% and +8.58%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
2 min read
